HOME
CONTACT US
Who We Are
Our Story
Corporate History
Stock Price History
Settlement Key Features
Growth Strategy
Our Patents
Leadership
Management
Board of Directors
Scientific Advisory Board
Committees
Pipeline
OVERVIEW
BASAL CELL CARCINOMA NEVUS SYNDROME
WHAT IS BCCNS
BCCNS’ UNMET NEED
TREATMENT OF BCCNS WITH ITRACONAZOLE
CLINICAL TRIALS & RESULTS
FORWARD LOOKING
LUNG CANCER
NON-SMALL CELL LUNG CANCER
ITRACONAZOLE IN NSCLC
CLINICAL TRIALS & RESULTS
FORWARD LOOKING
PROSTATE CANCER
METASTATIC, CASTRATE-RESISTANT PROSTATE CANCER
ITRACONAZOLE IN mCRPC
CLINICAL TRIALS & RESULTS
FORWARD LOOKING
Repurposing Itraconazole in Oncology (PDF)
Investors & Media
News Releases
Events & Presentations
Stock Information
Interactive Chart
Historical Price Lookup
Financials-Filings
SEC Filings
Fundamentals
Annual Reports – Proxy Satements
Corporate Governance
Committee Composition
Investor Resources
Who We Are
Our Story
Corporate History
Stock Price History
Settlement Key Features
Growth Strategy
Our Patents
Leadership
Management
Board of Directors
Scientific Advisory Board
Committees
Pipeline
OVERVIEW
BASAL CELL CARCINOMA NEVUS SYNDROME
WHAT IS BCCNS
BCCNS’ UNMET NEED
TREATMENT OF BCCNS WITH ITRACONAZOLE
CLINICAL TRIALS & RESULTS
FORWARD LOOKING
LUNG CANCER
NON-SMALL CELL LUNG CANCER
ITRACONAZOLE IN NSCLC
CLINICAL TRIALS & RESULTS
FORWARD LOOKING
PROSTATE CANCER
METASTATIC, CASTRATE-RESISTANT PROSTATE CANCER
ITRACONAZOLE IN mCRPC
CLINICAL TRIALS & RESULTS
FORWARD LOOKING
Repurposing Itraconazole in Oncology (PDF)
Investors & Media
News Releases
Events & Presentations
Stock Information
Interactive Chart
Historical Price Lookup
Financials-Filings
SEC Filings
Fundamentals
Annual Reports – Proxy Satements
Corporate Governance
Committee Composition
Investor Resources
Search:
INHIBITOR THERAPEUTICS
Innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders
